Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784330 | 0.82 | TSHR (0.61) | TSHRRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12447971 | 0.80 | MAPT (0.54) | TSHRSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL3988266 | 0.80 | KMT2A (0.62) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL4195006 | 0.80 | KMT2A (0.62) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL3988268 | 0.80 | KMT2A (0.62) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL4411591 | 0.80 | CA1 (0.58) | TSHRRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4411590 | 0.80 | CA1 (0.58) | TSHRRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7825125 | 0.79 | KMT2A (0.64) | TSHRRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7825122 | 0.79 | KMT2A (0.64) | TSHRRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9422337 | 0.79 | SMN1; SMN2 (0.73) | TSHRRAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | Pelemed Co., Ltd. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20200270229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER | Pelemed Co., Ltd. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER | FLT3, ABL1, MCL1 | TSHR 3477/4885RAB9A 4337/4885SMN1; SMN2 4518/4885 |
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | FLT3, ABL1, MCL1 | TSHR 3477/4885RAB9A 4337/4885SMN1; SMN2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.